+44 (0)1865-842-976 (UK)

+91 20 30108 270 (ASIA)

Novel findings in the field of neuroscience are yielding new technologies and techniques to meet the critical medical needs, in the area of brain and nervous system disorders. Recent innovations have made neuroscience the most exciting field of research in modern day science. Understanding the functions of the brain and how it works, are the fastest developing areas- having implications for, treatments of life altering neurological and psychiatric illnesses. Progress in understanding the brain function and brain disorders are often enabled by innovative technology and to ensure continued advances in brain science, Industry-Academic-Government partnerships are needed. Neuroscientist researchers face tremendous challenges in developing and bringing new treatments and technologies. Despite the fact that, the challenges related to brain research are abundant, significant progress continues to be made. 

The 2nd Annual Neuroscience R&D Technologies Conference, organized by MnM Conferences, on 29-30 September 2016, at the Sheraton Skyline Hotel in London, UK - aims at creating a platform for all the stakeholders to discuss, brainstorm and find answers to the ongoing question & challenges in the neuroscience research and recent advancements in neuroscience R & D technologies.


Post Show Report 2015

Click here to view post show report of Neuroscience R&D Technologies Conference 2015.

 


Testimonials 2015

“The Neuroscience R&D Technologies Conference in Barcelona brought together experts in the field to discuss the latest advancements of established and new enabling technologies addressing key challenges in the field of CNS drug development. The agenda covered a broad spectrum of topics ranging from Neuroinformatics to Translational Imaging. The vivid mix of plenary talks and panel discussions with plenty of opportunities for networking completed the first edition of this new conference. Looking forward to the next ‘number’.“

Georg Terstappen, Neuroscience Discovery AbbVie, Germany


“This was an important meeting as it brought together leaders from industry and academia to discuss current challenges in Neuroscience drug discovery and how new technologies could contribute to potential solutions.”

Anirvan Ghosh, F. Hoffmann-La Roche, Switzerland


“The Neuroscience R&D Technologies Conference provided a wonderful forum to learn about the latest experimental techniques. There was a good mix of speakers and attendees with different backgrounds coming from both industry and academia as well as contract research organizations. The discussions were very stimulating and engaged providing great networking opportunities. “

Rafal Kaminski, UCB Biopharma, Belgium


“Thank you for this very nice and inspiring conference. The presentations and discussions allowed an excellent overview of new approaches on drug discovery for CNS. I appreciated especially the nice atmosphere and opportunities for networking. “

Dr. Olaf Schroeder, NeuroProof GmbH, Germany


 

conference Registration Form

-


 
  

CategoryCost
Academic Delegate£399
Industry Delegate £499
Solution Provider Delegate£995

Agenda

Key Highlights
  • Imaging technologies for early go/no-go decisions
  • Blood Brain Barrier in CNS Drug Discovery
  • Neuroinformatics
  • Computational disease drug response models
  • Translational animal models
  • Neuromodulation & Deep Brain Stimulation
  • Investing & partnering in neurotechnology
  • Neuro Stem cells for drug discovery
  • Biomarker and Drug Discovery – Neurodegenerative Diseases

Who Should Attend ?

From Pharmaceutical, Academics and Research Institutes

Chief Scientific Officer/Directors/Heads/VP/Managers/Senior Scientists/ Principal/ Scientist/ Neuroscientists/ Project Leaders/ Professors/Research Fellows in:

  • Neuroscience Discovery
  • Neuropharmacology
  • CNS Discovery
  • Neuroimaging / Brain Imaging
  • Neurodegenerative diseases
  • Translational Neuroscience
  • Computational Neuroscience
  • Neuroinformatics
  • Pre-clinical research
  • Clinical Research 
  • Integrative Neuroscience
  • Neurotechnology
  • Neurology R&D
  • Neuroscience
  • Neuroengineering
  • Neuromorphic engineering


Why attend?

  • First ever conference on application of technology in developing neurological treatments 
  • Meet global heads of neuroscience from the industry and Academics
  • 100+ neuroscience professionals attending
  • Access to online presentations on-demand post-summit
  • Case studies presented from leading technology collaborations 
  • Interactive panel and breakout sessions

SPEAKERS

  • Marcus Kaiser

    Professor of Neuroinformatics Interdisciplinary Computing and Complex Biosystems (ICOS) Research Group, School of Computing Science, Newcastle University
  • Georg Terstappen

    Director and Head of Biology Department, Neuroscience Discovery AbbVie , Germany
  • Rafal Kaminski

    Senior Director Neuroscience TA UCB Biopharma, Belgium
  • Zameel Cader

    Director and Principal Scientist, IMI StemBANCC University of Oxford, UK
  • Eugenii A. (Ilan) Rabiner

    Head of Imaging Applications & Chief Medical Officer, Imanova Reader in Molecular NeuroImaging, Centre for Neuroimaging Sciences, IoPPN, King’s College, London, UK
  • Ago Rinken

    Head of Chair, Professor of Bioorganic Chemistry Institute of Chemistry, University of Tartu, Estonia
  • Luc Ver Donck

    Head of Alzheimer Disease Animal Models, Neuroscience Discovery Janssen Pharmaceuticals, Belgium
  • Dr. Alexander D. Crawford

    Principal Investigator, Chemical Biology Group | Luxembourg Centre for Systems Biomedicine (LCSB), Université du Luxembourg
  • Winston Hide

    Chair of Bioinformatics and Computational Biology Sheffield Institute for Translational Neuroscience, University of Sheffield, UK
  • Thomas Knöpfel

    Chair of Optogenetics and Circuit Neurosciences| Division of Brain Sciences, Department of Medicine, Imperial College London
  • Tilo Kunath

    Group Leader, Parkinson’s UK Senior Research Fellow, MRC Centre for Regenerative Medicine & Euan MacDonald Centre for Motor Neurone Disease Research, The University Of Edinburgh
  • Trevor W. Robbins

    Professor, Cognitive Neuroscience and Experimental Psychology, Director, Behavioural and Clinical Neuroscience Institute Head of Dept., Psychology, University of Cambridge, UK
  • Kei Cho

    Chair of Neuroscience, MRC Centre for Synaptic Plasticity, University Of Bristol UK.
  • Dr. Janet Nicholson

    Director, CNS Diseases Research Boehringer Ingelheim, Germany
  • Thomas R. Jahn

    Lab Head, Disease Model Systems, Neuroscience Discovery– Biology Department AbbVie, Germany
  • Sandra Robelet

    Pre-Clinical Study Director Syncrosome, France
  • Prof. Gordon Pipa

    Professor and Chair of the Neuroinformatics Department, Institute of Cognitive Science University of Osnabrueck, Germany
  • Paul Karila

    VP Discovery Services Cellectricon, Sweden
  • Elena Dragicevic

    Senior Scientist, Nanion Technologies, Germany
  • Morgane Rouault

    Application and Support Scientist Advance Cell Diagnostics, Italy
  • Tristan Pritchard-Meaker

    Senior Business Development and Sales Northern & Eastern Europe, Axiogenesis
  • Dr. Olaf Schroeder

    Chief Executive Officer NeuroProof GmbH, Germany
  • Dr. Karlijn Wilschut

    Senior Scientist Application Development Mimetas BV, Leiden, The Netherlands
    

SPONSORS


Silver Sponsor

Axio Genesis

Axiogenesis
Axiogenesis is a leading provider of commercial-grade in vitro differentiated cell types derived from human induced pluripotent stem cells (iPSCs), broadly applicable for drug discovery, safety / toxicity screening, as well as disease modeling. Axiogenesis neural cell portfolio spans Peri.4U peripheral neurons (structural and functional toxicity assays, novel neurotoxin screening), Dopa.4U dopaminergic neurons (neurodegenerative disease models, neurotoxicity screening), and Astro.4U astrocytes for neuronal co-culture. Products in development include iPSC-derived sensory neurons and CNS neurons.


Sponsors/Exhibitors

Syncrosome

Syncrosome

As more than 60% of new drugs fail in phase 2, we have chosen to focus our activities since 2000 on preclinical in Vivo Efficacy Studies to offer better predictability and anticipate clinical results.
Our main activities consit in :

- In vitro Drug Efficacy Studies for Central Nervous System with models in Parkinson, Alzheimer and Stroke disease.

 - In vivo Drug Efficacy Studies for:

  • Central Nervous System,
  • Cardiometabolism,
  • Respiratory,
  • Gastroenterology,

- CNS-PK with a special focus in the study of the Blood Brain Barrier passage and/or Neurotransmitter monitoring.
- Early bioavailibity studies (PK/PD) on rodents and non-rodents.


Neuro-sys

Neuro-sys

Neuro-Sys is an innovative French Drug Discovery and Services company focusing on neurodegenerative diseases. Neuro-Sys has developed specific preclinical models of neurological diseases to accurately determine the pharmacological profiling of leads compounds and explore their underlying mechanism of action. All processes are standardized and automated.

Neuro-Sys also develops its proper drug discovery programs based on an innovative and unique approach.


Nanion TechnologiesNanion Technologies

Founded in 2002 Nanion Technologies has become known for its high quality instruments for ion channel research (Port-a-Patch, Patchliner and SyncroPatch product families) and has expanded its product portfolio to include impedance recordings (CardioExcyte 96), parallel bilayer recordings (Orbit), and parallel membrane transporter protein recordings (SURFE2R). Furthermore, Nanion also carries Axion's multi-electrode array (MEA) systems in Europe and China. Nanion has headquarters in Munich, Germany, and sites in the USA, Copenhagen, China and Japan.


 

ChemometecChemoMetec

ChemoMetec develops and manufactures high quality automated cell counter-analysers. Specialised counting functions include aggregated cells, cells growing on micro-carriers, Adipose Derived Stem Cells. Advanced cell analysis functions include plug-and-play assays for Cell Cycle, Apoptosis, GFP and more. Helping to streamline R&D and production work-flows for maximum efficiency.



Supporting drug discovery teams in pharma, biotech and academic organizations, our Discovery Services provide cutting-edge phenotypic insight to help shorten lead times and reduce costs. Our compound profiling services in excitable cells, native tissues and stem cells provide researchers with early, physiologically-relevant drug target validation and compound characterization for decision-making value.

• Fully collaborative services

• Advanced discovery platform

• Biologically relevant disease models

• Specialists in CNS and pain diseases


ACD

Visualize expression for multiple genes simultaneously in any tissue from any species

Advanced Cell Diagnostics’ RNAscope® in situ hybridization technology delivers unrivaled single-molecule sensitivity and specificity - with the multiplexing capability for the detection of multiple markers at once, enabling exquisite characterization of cell populations within the nervous system. Same-day results and automated assays mean you can get the data you seek quickly, easily, and all backed by our performance guarantee. Learn more at acdbio.com/neuroscience


Brains-Online

Brains On-Line
Brains On-Line provides preclinical contract research services to facilitate the drug development process, with expertise in disorders of the central nervous system (CNS). Using a broad spectrum of research techniques, we strive to provide our customers full insight into the possibilities and therapeutic targets of their compounds. We provide our research services with the highest degree of flexibility, and highest standards of quality and scientific integrity as required in modern Research & Development.


NeuroProof

NeuroProof
NeuroProof is a global leader and preferred partner in the field of microelectrode array (MEA)-based phenotypic screening of neuronal cell cultures from mouse or human stem cell derived.  NeuroProof offers screening services and state-of-the-art mathematical expertise for the phenotypic analysis of test agents on neuronal network activity.  The services comprise the growing of neuronal cultures on MEA chips, medium throughput screening of test agents, high quality recording of spontaneous and compound-induced network activity, state-of-the-art mathematical analyses, and sophisticated pattern recognition methods.  The unique platform is well suited to identify and characterize effects of test agents on neuronal network activity and brain cell functioning.  




Posters

2nd Annual Neuroscience R&D Technologies Conference is an ideal platform for researchers and academicians to showcase their findings in front of expert industry professionals.

All Poster presentations will take place in breaks and alongside the breakout sessions of the congress.  All the presentation will be displayed in a dedicated area along with accepted posters from both industry & Academia.

To present a poster the presenter should be registered as a delegate and the poster space will be assigned on a first come first basic (Subjected to successful registration & space availability). In order to present a poster at the forum, you need to be registered as a delegate.

Please note that there is limited space available and posters space is assigned on a first come first served basis (subject to checks and successful registration).

Posters should be presented as A0 or US equivalent, size E (841mm x 1189mm or 34 x 44 inches respectively) in portrait orientation.

For further details and requirements please contact:

Ajay Nimbalkar
Email: ajay.nimbalkar@mnmconfernces.com
Tel:+91 20 3010 8270

CategoryCost
Academic delegatesFree
Industry and Solution Provider delegates£75

Posters Submission Form


 
  

SUPPORTING ASSOCIATIONS

British Neuroscience Association

The British Neuroscience Association is the largest UK organisation representing and promoting all aspects of neuroscience and neuroscientists.  Our members' interests cover the whole range of neuroscience, from ion channels to whole animal behaviour to neuroscience applications in the clinic and beyond, and undertakes a variety of activities to meet its overarching goal to, ‘preserve and protect health and advance public education in neurosciences related to health and disease’.


 

European Association of Neurosurgical Societies (EANS)

The European Association of Neurosurgical Societies (EANS) is a fast-growing, independent association, both of European neurosurgical societies and of individual neurosurgeons all over the world. Our aim is to enable our members to enhance the care they deliver to their patients by facilitating the exchange of scientific information at the highest level. In pursuit of this goal, we arrange a wide range of meetings, symposia and educational courses, including the European Congress of Neurosurgery and the highly regarded European Training Courses in Neurosurgery. 

 


 

Spanish Federation of Parkinson’s Disease

Spanish Federation of Parkinson Disease (FEP) was born in 1996 with the primary goal of improving the quality of life for those affected by Parkinson´s Disease and their families. Twenty years later, the FEP is formed by 48 associations, spread over Spain and bringing together more than 12,000 associates.

The FEP is currently working on different lines of action such as providing information and advice, covering healthcare and social needs, raising awareness of PD, promoting research and encouraging public administration.


European Society for Neurochemistry

The European Society for Neurochemistry (ESN) was founded in 1976 with the objectives to advance Neurochemistry for the public benefit and to promote the development of Neurochemistry in Europe. ESN is a sister society of the International Society for Neurochemistry (ISN) and a member of Federation of European Neuroscience Societies (FENS). Information about the ESN initiatives you can find at http://www.neurochemsoc.eu. To be ESN member,please fill the application at http://www.neurochemsoc.eu/membership/esn.html and become member of ESN, ISN and FENS with one single application.


NeuroModec

NEUROMODEC is a free online service created to support the development of neuromodulation through the integration of shared resources, research tools, professional standards, events and inter-institution collaboration. Consistent with our mission to freely disseminate information, Neuromodec.com serves to advance neuromodulation basic research, technologies and the clinical implementation of the associated therapies.



The Neurological Alliance

The Neurological Alliance is the only collective voice for 80 patient organisations working together to make life better for millions of people in England with a neurological condition.

We work with our member organisations to campaign nationally and locally to ensure better services and outcomes for all those with a neurological condition.


The International Federation of Clinical Neurophysiology (IFCN)The International Federation of Clinical Neurophysiology (IFCN) has members operating in 59 countries globally. The main goal of the IFCN is to promote education and the highest level of practice of Clinical Neurophysiology to improve health.





BioPartner BioPartner is an independent, accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK Life Science companies. BioPartner's delegations promote the UK presence at major international biopharma conferences, and companies are assisted with access to government grants and heavily discounted entry fees. Through the BioPartnership Programme, members receive extra benefits and support to effectively trade overseas.


OBN

OBN is the largest not-for-profit R&D company membership organisation in the UK, supporting and bringing together the UK’s innovative life sciences companies, corporate partners and investors. Our Member companies are located across the Golden Triangle and beyond to Nottingham, The Midlands, Manchester and Scotland benefiting from our networking, partnering, purchasing, advising, training, and advocacy activities.



Science Marketplace

Science Marketplace is a free platform which aims to facilitate all sorts of scientific exchanges including collaborations, services, jobs, studentships and conferences. In other words, to provide an online marketplace for scientists of all fields. Please post your expertise to establish new collaborations, showcase your company or university services, advertise jobs, conferences, etc.


Venue

Venue

2nd Annual Neuroscience R&D Technology Conference will be held at the Sheraton Skyline Hotel in United Kingdom.

The Sheraton Skyline Hotel

Heathrow Airport, Bath Road.
Hayes, United Kingdom

Hotel Discount Link

Accommodation is available at the The Sheraton Skyline Hotel at a preferential rate from £143.50 per night including tax & breakfast. To make your reservation, please click here before 5th September, Subject to availability please book early to avoid disappointment, (Please note that we do not authorise any 3rd party agencies (e.g. Exhibitors Housing Management) to book on our behalf and, occasionally, companies fraudulently try to represent us. If you are contacted by anyone other than me regarding your accommodation requirements for this event, please let me know immediately)

About the Venue

Conveniently located beside London Heathrow Airport, the Sheraton Skyline Hotel London Heathrow offers quick access to all the hub’s terminals. Featuring 350 large and comfortable guest rooms, we are so much more than just an airport hotel.

18 meeting rooms include the high-tech Doha Room and boardrooms ideal for high profile events. Impress your colleagues with The International Suite and our Sky Garden, unique with its indoor pool and Sky Bar.

For further Information please contact:

Steve Hambrook | Conference Director

Email: steve.h@mnmconferences.com